Compare RCUS & PRVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | PRVA |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2018 | 2021 |
| Metric | RCUS | PRVA |
|---|---|---|
| Price | $26.12 | $23.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $30.27 | ★ $30.71 |
| AVG Volume (30 Days) | ★ 999.3K | 699.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.64 |
| EPS | N/A | ★ 0.18 |
| Revenue | $247,000,000.00 | ★ $2,122,842,000.00 |
| Revenue This Year | N/A | $18.19 |
| Revenue Next Year | $45.62 | $10.72 |
| P/E Ratio | ★ N/A | $131.06 |
| Revenue Growth | N/A | ★ 22.26 |
| 52 Week Low | $7.06 | $18.78 |
| 52 Week High | $26.40 | $26.51 |
| Indicator | RCUS | PRVA |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 62.11 |
| Support Level | $19.62 | $22.63 |
| Resistance Level | N/A | $24.13 |
| Average True Range (ATR) | 1.56 | 0.76 |
| MACD | 0.30 | 0.22 |
| Stochastic Oscillator | 69.54 | 79.90 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.